Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | IAPP | P10997 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | SELL | P14151 | 2/20 | 0.45 |
| ▸ | SELP | P16109 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11051603 | 0.82 | IAPP (0.46) | IAPP | |
| SCHEMBL30485631 | 0.82 | IAPP (0.70) | POLBIAPPNPSR1 | |
| SCHEMBL26046412 | 0.82 | IAPP (0.70) | IAPP | |
| SCHEMBL244943 | 0.82 | IAPP (0.70) | POLBIAPPNPSR1 | |
| SCHEMBL26046352 | 0.81 | POLB (0.45) | POLBIAPPNPSR1 | |
| SCHEMBL30940438 | 0.80 | AKR1B1 (0.58) | POLBSELLSELP | |
| SCHEMBL8685874 | 0.80 | AKR1B1 (0.58) | POLBSELLSELP | |
| Ammonia Solution, Strong SCHEMBL31621217 | 0.80 | IAPP (0.68) | POLBIAPPNPSR1 | |
| SCHEMBL21317652 | 0.80 | POLB (0.59) | POLBIAPPNPSR1 | |
| SCHEMBL23816613 | 0.79 | PIK3CA (0.49) | IAPPSELLSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746364-B2 | Enzymatic synthesis of kavalactones and flavokavains | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746364-B2 | Enzymatic synthesis of kavalactones and flavokavains | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2023-09-05 | — | — | US | disclosed |
| US-11739354-B2 | Enzymatic synthesis of kavalactones and flavokavains | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739354-B2 | Enzymatic synthesis of kavalactones and flavokavains | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2023-08-29 | — | — | US | disclosed |
| US-20220002769-A1 | ENZYMATIC SYNTHESIS OF KAVALACTONES AND FLAVOKAVAINS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-01-06 | — | — | US | disclosed |
| US-20220002768-A1 | ENZYMATIC SYNTHESIS OF KAVALACTONES AND FLAVOKAVAINS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-01-06 | — | — | US | disclosed |
| US-10941429-B2 | Enzymatic synthesis of kavalactones and flavokavains | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2021-03-09 | — | — | US | disclosed |
| US-20190271015-A1 | ENZYMATIC SYNTHESIS OF KAVALACTONES AND FLAVOKAVAINS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2019-09-05 | — | — | US | disclosed |
| US-8268293-B2 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8106233-B2 | Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing | MERCK PATENT GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
| US-20080152603-A1 | Antioxidants | SUSONITY Commercial GmbH (DE) | 2008-06-26 | — | — | US | disclosed |
| EP-1871735-A1 | ANTIOXIDANTS | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| EP-1871339-A1 | UV PROTECTION | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006111233-A1 | ANTIOXIDANTS | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006111234-A1 | UV PROTECTION | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080152603-A1 | Antioxidants | GPX4, GPX1, CAT | POLB 259/4885IAPP 1118/4885NPSR1 2684/4885 |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | HPD, HAAO, UGT1A6 | POLB 236/4885IAPP 4855/4885NPSR1 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.